Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
35.42m
Last Price
$0.84
52-Week Range
$0.66 - $1.66
08/28/2025 05:58 PM EDT